section name header

Indications

REMS

Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Based on concurrent use with ritonavir

Derm: acute generalized exanthematous pustulosis, rash, DRUG RASH WITH EOSINOPHILIA AND SYSTEMIC SYMPTOMS (DRESS), STEVENS-JOHNSON SYNDROME, TOXIC EPIDERMAL NECROLYSIS.

Endo: Graves' disease, hyperglycemia.

GI: autoimmune hepatitis, constipation, diarrhea, HEPATOTOXICITY, nausea, vomiting.

Metab: body fat redistribution.

MS: polymyositis.

Neuro: Guillan-Barré syndrome.
Misc: immune reconstitution syndrome.

Interactions

Drug-Drug:

Drug-Natural Products:

Availability

(Generic available)

Route/Dosage

Genotypic testing of the baseline virus is recommended prior to initiating treatment in therapy-experienced patients. This testing is performed to screen for darunavir resistance associated substitutions, which may be helpful in determining whether the patient's HIV will be susceptible to darunavir.

US Brand Names

Prezista

Action

Therapeutic Effects:

Classifications

Therapeutic Classification: antiretrovirals

Pharmacologic Classification: protease inhibitors

Pharmacokinetics

Absorption: Without ritonavir: 37% absorbed following oral administration; with ritonavir: 82%. Food absorption by 30%.

Distribution: Unknown.

Protein Binding: 95%.

Metabolism/Excretion: Extensively metabolized by the CYP3A isoenzymes. 41% eliminated unchanged in feces, 8% in urine.

Half-life: 15 hr.

Time/Action Profile

ROUTEONSETPEAKDURATION
POunknown2.5–4 hr12 hr

Patient/Family Teaching

Pronunciation

da-RU-na-veer